Navigation Links
Alexion Pharmaceuticals to Present Data on Soliris(R) (Eculizumab) and PNH at the 2007 American Society of Hematology (ASH) Annual Meeting

CHESHIRE, Conn., Dec. 7 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that data relating to paroxysmal nocturnal hemoglobinuria (PNH), as well as to Soliris(R) (eculizumab), a treatment for patients with PNH, will be presented at the 2007 American Society of Hematology Meeting, December 8 - 11 in Atlanta.

The following abstracts will be presented in a poster session on red cell regulation and disorders of production on Monday, December 10, 2007. The session will open at 10:30 a.m. and poster presentations will be held from 5:00 to 7:00 p.m. for each abstract. Additional information can be accessed through the links provided below.

-- Poster # 897-III: "High Incidence of Progression to Chronic Renal

Insufficiency in Patients with Paroxysmal Nocturnal Hemoglobinuria

(PNH)" Dr. Peter Hillmen et al.

-- Location: Hall B3 and B4


-- Poster # 891-III: "Sustained Improvements in Transfusion

Requirements, Fatigue and Thrombosis with Eculizumab Treatment in

Paroxysmal Nocturnal Hemoglobinuria" Dr. Gerard Socie et al.

-- Location: Hall B3 and B4


-- Poster # 902-III: "Disease-Related Symptoms Reported across a Broad

Population of Patients with Paroxysmal Nocturnal Hemoglobinuria" Dr.

Gabrielle Meyers et al.

-- Location: Hall B3 and B4


The following abstract will be presented in an oral session on red cell regulation and disorders of production on Tuesday, December 11, 2007. The abstract and presentation information can be accessed at the link provided below.

-- Publication Number 840: "Significant Disease Burden in Paroxysmal

Nocturnal Hemoglobinuria Patients with Lower Levels of Hemolysis,

Mild Anemia and Minimal Transfusion: Clinical Improvement with

Eculizumab Therapy" Dr. Monica Bessler et al.

-- Location: Rooms B213-B214

-- Tuesday, December 11, 2007 - 8:45 a.m.


SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Alexion Pharmaceuticals Invites You to Participate in its Third Quarter 2007 Results Conference Call and Web Cast
2. Alexion to Present at Investor Conferences
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... direct sauna parts and accessories. , Sauna accessories help improve the bather experience ... and personality. From basic styles for the purist looking for simplicity in design ...
(Date:11/25/2015)... ... 2015 , ... For the first time, Vitalalert is donating half of its ... The partnership between the two groups began in 2014 with Vitalalert pledging a portion ... International was founded in 1954 and is an international Christian-based health organization whose mission ...
(Date:11/25/2015)... , ... November 25, 2015 , ... On November 25, ... center for the Narconon network, announced the release of a new cutting edge recovery ... Narconon organization has been working with drug- and alcohol-addicted individuals with the purpose to ...
(Date:11/25/2015)... ... 2015 , ... Smiles by Stevens is pleased to announce the ... While many patients are aware of the benefits of Botox® in the treatment of ... suffering with discomfort, soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... In an ... Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of ... and surgical intensive care units (totaling 30 beds) from May 2014 through October 2015 ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Italian therapeutic drug monitoring market, including ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
(Date:11/25/2015)... MINNEAPOLIS , Nov. 25, 2015  ARKRAY ... care products, continues to provide evidence demonstrating the accuracy ... the World Congress on Insulin Resistance, Diabetes and Cardiovascular ... showed that both the Company,s GLUCOCARD ® 01 ... met high accuracy requirements. The ability to accurately measure ...
Breaking Medicine Technology: